Zenas’ multiple sclerosis drug slows new brain lesions in mid-stage trial

Zenas BioPharma’s multiple sclerosis therapy succeeded in a mid-stage trial. The biotech's shares {$ZBIO} were up about 18% on Monday morning. The company said Monday that 116 patients with relapsing disease ...